Document:

Exhibit 10.66

 

MATERIALS TRANSFER AGREEMENT

 

This
Agreement is among Advanced Cell Technology, Inc. (“ACT”), and Charlotte
Farin, Ph.D. and Peter Farin, D.V.M., Ph.D. (Dr. Charlotte Farin and Dr.
Peter Farin collectively referred to herein as “Researcher”), professors at
North Carolina State University in Raleigh, North Carolina (“The Institution”).
The Institution and the Researcher are collectively referred to in this
Agreement as the “Recipients.”

 

The
parties hereby agree as follows:

 

1.                                      Requested Materials. The term “Materials” shall mean the
following tangible materials that are requested by Researcher and furnished by
ACT under the terms of this Agreement:

 

Three
cloned gaur fetuses

 

“Materials”
shall also include any other materials routinely produced through use of such
tangible materials, including, for example, any progeny derived from a cell
line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated
from isolated DNA or RNA, recombinant proteins produced by a recombinant cell line,
recombinant proteins produced through use of isolated DNA or RNA, and
substances routinely purified from any source material included in the
materials (such as recombinant proteins isolated from a cell extract or
supernatant by non-proprietary affinity purification methods).

 

2.                                      Limited Use of Materials. The Recipients agree to use the Materials
only for the following experimental research under the direct supervision of
Researcher, and not for any other purpose:

 

To
evaluate the fetuses for any gross developmental abnormalities

 

In
consideration of the evaluation of the Materials, ACT shall include Recipients
as authors in any publication(s) making use of results obtained from said
evaluation.

 

3.                                      Compliance with Law; No Use With
Experiments on Human Subjects. The Recipients shall use the Materials only in compliance with all
applicable federal, state and local laws and regulations. The Recipients shall
not use the Materials in any in vivo experiments on human subjects
without the prior written consent of ACT.

 

4.                                      Limited Disposition of Materials. The Materials shall remain on the premises
of the Institution. The Recipient shall not distribute any Materials to any
third party other than employees or students of Institution who are working
under the supervision of Researcher. Upon completion of the research, or sooner
at the request of ACT, the Recipient shall at the Instruction of ACT either
destroy or return any unused Materials.

 

1

 

5.                                      Ownership of Materials. The Recipient acknowledge and agrees that
all title and intellectual property rights in the Materials are and shall be
owned by ACT. The Recipient agrees to execute and deliver and documents of
assignment or conveyance to effectuate the ownership rights of ACT in the
Materials.

 

6.                                      Ownership of Intellectual
Property. The Researcher
shall promptly inform ACT they intend to commercialize, to file a patent
application claiming, or to assert any intellectual property rights in any
research results obtained using the Materials. ACT agrees to negotiate in good
faith their respective ownership of the research results and any intellectual
property rights therein based on their relative contributions to such rights
and on any applicable laws relating to ownership of such rights, including
without limitation those relating to inventorship and authorship.

 

7.                                      License Option to ACT. Recipients shall notify ACT promptly of any
discoveries, inventions, data, modifications, new substances, and other results
of any research using the Materials (“Research Results”). To the extent
permitted by law and any conflicting obligations to non-profit sponsors of
research, the Recipient hereby grants ACT a first option to obtain an
exclusive, worldwide license under any intellectual property rights in any
Research Results (the “License Option”). ACT may exercise the License Option upon
written notice and the Recipient within thirty (30) days from the date upon
which ACT receives notice of the relevant Research Results. In the event that
ACT elects to exercise the License Option, the parties shall attempt to
negotiate in good faith the license agreement containing commercially
reasonable terms and pricing. If the parties are unable to reach agreement
within ninety (90) days after the date upon which ACT exercised the license
option (the “Negotiation Period”). Then the Recipient will be free to offer
such rights to third parties; provided, however, that for a period of one (1) year
after the Negotiation Period the Recipient may only offer such rights to third
parties on terms and pricing which in the aggregate are no more favorable than
those last offered to ACT, unless more favorable terms and pricing have first
been offered in writing to ACT and either (i) ACT has declined in writing
to accept such terms and pricing or (ii) ACT has not responded after a
period of thirty (30) days from the date of such offer. The Recipient shall not
use the Materials in research that is subject to a licensing obligation to another
commercial entity without the prior written consent of ACT.

 

8.                                      Publication Rights. Researcher shall have the unrestricted right
to publish the results of any research using the Materials; however, in order
to prevent the inadvertent loss of patent rights, the Recipients, shall provide
ACT with pre-prints or abstracts of any proposed presentation or paper
describing any Research Results at least sixty (60) days prior to publication.

 

9.                                      No Warranties. Any Materials delivered pursuant to this
Agreement are understood to be experimental in nature and may have hazardous
properties. ACT MAKES NO REPRESENTATIONS AND EXTENDS NO
WARRANTIES OF ANY KIND. EITHER EXPRESSED OR IMPLIED. WITH RESPECT TO THE
MATERIALS, AND SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, OR

 

2

 

THAT THE USE OF THE MATERIALS WILL
NOT
INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF A
THIRD
PARTY.

 

10.                                 Indemnification.
The Recipient assumes all liability for damages which may arise from the use, storage, or disposal of the
Materials. To the extent permitted by law,
each party shall indemnify and hold the other harmless from any costs and
expenses, including reasonable attorneys’ fees, resulting from any claim or demand
arising from a breach of any of the terms or conditions of this Agreement.

 

The parties
hereby Execute this Agreement effective as the date last written below.

 

 

	
   

  	
  ADVANCED CELL TECHNOLOGY,
  INC.

  
	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  /s/ Philip Damiani

  	
   

  	
  By:

  	
  /s/ Robert Lanza M.D

  	
   

  
	
  Witness

  	
  Printed Name:

  	
  Robert Lanza M.D

  	
   

  
	
   

  	
  Title: 

  	
  VP Bust sci. Development

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Charlotte E. Farin

  	
   

  
	
  Witness

  	
  Printed Name: 

  	
  Charlotte E. Farin

  	
   

  
	
   

  	
  Title: 

  	
  Professor – North Carolina
  State University

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Peter Farin

  	
   

  
	
  Witness

  	
  Printed Name: 

  	
  Peter Farin

  	
   

  
	
   

  	
  Title: 

  	
  Professor – North Carolina
  State University

  	
   

  
	
   

  	
   

  
	
   

  	
  Approved
  for NC State University

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Mark
  Crewell 

  	
   

  
	
  Witness

  	
  Printed Name:

  	
   Mark
  Crewell

  	
   

  
	
   

  	
  Title: 

  	
  Associate
  Vice Chancellor for
Technology Transfer &
  Industry Research

  
	
   

  	
   

  	
  3/20/00

  
													

 

3Exhibit 10.67

 

SPONSORED RESEARCH AGREEMENT

 

This SPONSORED
RESEARCH AGREEMENT (“Agreement”) is made as of this 15th day of May, 2000 by
and between ADVANCED CELL TECHNOLOGY, INC., a Delaware corporation located at
One Innovation Drive, Worcester, Massachusetts 01605 (“ACT”), and the Carl H.
Lindner, Jr. Family Center for Research of Endangered Wildlife, the research
division of the Cincinnati Zoo and Botanical Garden, an Ohio nonprofit
Corporation located at 3400 Vine Street, Cincinnati, Ohio 45220 (“CREW”)
governing research to be conducted in the laboratories of CREW.

 

EXPLANATORY STATEMENT

 

WHEREAS, CREW is engaged in research and development of embryo
transplant technology in domestic cats and wild felids; and

 

WHEREAS, ACT is engaged in the research, discovery and development of
cloning of mammals; and

 

WHEREAS, ACT possesses unique knowledge and experience in substantive
fields relating to cell and molecular biology, superovulation and oocyte
collection, embryo manipulation and embryo transfer, of mammals; and

 

WHEREAS, ACT is interested in developing a cloned feline; and

 

WHEREAS, ACT intends to support research of CREW involving the
maintenance of research animals and procedures such as superovulation oocyte
recovery, embryo transfer, gestation, delivery and rearing of newborn animals;
and

 

WHEREAS, ACT desires to fund such research by CREW, and CREW desires to
undertake such effort on behalf of ACT;

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the Explanatory Statement, which is
made a substantive part hereof and which is incorporated herein by reference,
and in further consideration of the mutual covenants, agreements,
representations, and warranties contained in this Agreement, and other good and
valuable consideration, the adequacy and receipt of which is hereby
acknowledged, ACT and CREW expressly covenant, agree, represent, and warrant as
follows:

 

1.             DEFINITIONS

 

For purposes of this Agreement, the following definitions shall apply:

 

1.01         The
term “Confidential Information” means the Project Research results, the terms
and conditions of this Agreement, and any confidential or proprietary
information furnished

 

 

by one party (the “Disclosing Party”) to the other party (the “Receiving
Party”) in connection with the performance of the Project Research, which is
marked “Confidential” or “Proprietary,” or which, under all of the given
circumstances, ought reasonably to be treated as confidential information of
the disclosing party. Such Confidential Information may include, without
limitation, trade secrets, know-how, inventions, technical data or
specifications, testing methods, and research and development activities.

 

1.02         The
term “Parties” shall mean CREW and ACT.

 

1.03         The
term “Products, Inventions, and Know-how” shall mean any and all products, devices,
inventions, processes, methods, discoveries, inventions, know-how, techniques, improvements
(including derivatives or analogues), and/or commercially useful research products
or processes, including, but not limited to, materials, whether patentable or unpatentable,
whether trade secrets or susceptible to copyright or other forms of protection,
that are conceived, made, reduced to practice, and/or developed by CREW as a
result of, or related to, the Project Research performed during the Research
Term (including any extensions) and for a period of six (6) months
thereafter.

 

1.04         The
term “Project Funds” shall mean those funds paid by ACT to CREW to conduct the Project
Research in accordance with this Agreement.

 

1.05         The
term “Project Research” shall mean the research that CREW agrees to perform
under the terms and conditions of this Agreement described more fully in the
research plan contained in Attachment A, which is incorporated herein by
reference and made part of this Agreement, and such modifications of Attachment
A as may be mutually agreed upon in writing by duly authorized
representatives of ACT and CREW.

 

1.06         The
term “Project Team” shall mean the scientists and research technicians who are supported
in whole or in part by the Project Funds and/or who are participating in the Project
Research.

 

1.07         The
term “Research Term” shall mean the period commencing on May 15, 2000 and terminating
on November 1, 2000 or such earlier date as the Project Research is completed.
The Research Term may be extended by the mutual written consent of the duly
authorized representatives of CREW and ACT.

 

1.08         Other
terms may be defined in particular sections throughout this Agreement and
Exhibits or Attachments.

 

2.             RESEARCH
AND REPORTS

 

2.01         Conduct of Research. During the Research Term, CREW shall conduct the Project
Research on behalf of ACT in accordance with this Agreement. The Project
Research shall commence promptly by May 15, 2000 and all reasonable
efforts shall be made to complete it by November 1, 2000.

 

2

 

2.02         Periodic Meetings. During the Research Term, and upon the
delivery of the final research report, representatives of ACT and CREW shall
meet from time to time to discuss the planning and progress of the Project
Research.

 

2.03         Research Reports. CREW shall promptly and continually advise
ACT of the results of the Project Research and, at monthly intervals during the
Research Term, provide ACT with written progress reports concerning the Project
Research. A final written research report setting forth the results achieved
under and pursuant to the Project Research shall be submitted by CREW to ACT
within sixty (60) days after the termination of the Project Research. Such
final research report shall include a complete summary of the research carried
out and detailed experimental protocols of the research performed in the course
of the Project Research.

 

2.04         Copies of Data. CREW shall, throughout the term of this
Agreement and upon delivering the final research report, provide to ACT copies
of all data and other information generated by or on behalf of the Project Term
pursuant to this Agreement, including without limitation, all raw data obtained
as a result of studied conducted in the course of Project Research and all
experimental procedures developed under the Project Research in sufficient
written detail to permit ACT’s personnel to employ such procedures in their own
research. ACT shall have full access to all such data and records of CREW and
its Project Team. CREW shall maintain copies of all such data and other information
for at least five (5) years following the termination of the Research Term
and shall permit ACT continued access.

 

2.05         Principal Research Scientists. The Research at CREW will be
conducted by and under the direction of principal research scientists, who, as
of the date of this Agreement, shall be Dr. Bill Swanson and Dr. Terri
Roth (the “Principal Research Scientists”). During the Research Term, neither
of the Principal Research Scientists will serve as a principal research
scientist for, or participate as a key researcher in, any research, at CREW, or
elsewhere, that has the goals of the Project Research, i.e., primarily, to
produce cloned felines by transferring reconstructed embryos into recipient
females. In the event that either of the Principal Research Scientists are no
longer available or able to continue direction of the Project Research, CREW
shall promptly notify ACT and CREW may nominate a replacement satisfactory to
ACT; if CREW does not nominate a replacement within thirty (30) days or if that
replacement is unsatisfactory to ACT in its sole discretion, ACT may
immediately terminate funding of the Project Research, but retain those rights
set forth in Section 7 hereof.

 

2.06         Qualified Support. CREW has or has arranged for, and shall
maintain, qualified laboratory, technical, veterinary, clerical, and other
personnel that are necessary and desirable to support CREW’s obligations under
this Agreement. CREW will ensure that all personnel supporting CREW’s
obligations under this Agreement will adhere to the research plan attached
hereto as Attachment A.

 

2.07         Use of Funds. CREW shall use the funds provided under Section 5
in support of activities by the principal research scientist and the Project
Team in support of the Project

 

3

 

Research. During the Research Term, CREW shall not use funds provided
by a commercial entity, other than ACT to support either (a) the principal
research scientist’s and the Project Team’s activities under this Agreement or (b) activities
of the principal research scientist and/or the Project Team within the scope of
the Project Research. CREW has prepared an initial budget to guide CREW’s
expenditures for its research activities during the Research Term. This budget
has been approved by ACT as part of the research plan and has been made a part
of Attachment A. If the Research Term is extended, CREW shall prepare
budgets consistent with the then agreed upon research plan which shall be
submitted to, and reviewed and approved by, ACT and incorporated in the updated
research plans. Title to any equipment purchased by CREW with Project Funds may
be retained by CREW.

 

2.08         Compliance with Law. CREW agrees that all studies, research,
and testing done by, or on behalf of, ACT under this Agreement shall be
performed in strict compliance with all applicable laws, rules, and regulations
governing the conduct of studies, research, and testing at the site where such
studies, research, and testing are being conducted.

 

2.09         Acknowledgement of Risks Associated Project Research. CREW
and ACT understand and acknowledge that the Project Research is experimental,
that its characteristics and functionality are not fully understood, and that
there may be substantial risks associated with the unknown properties of the
products of the Project Research or any other scientific materials.

 

3.             CONCURRENT RESEARCH

 

3.01         ACT
acknowledges that CREW conducts, and will continue to conduct, research into
certain aspects of feline biology for the benefit of third parties, the subject
matter of which is not directly related or relevant to the subject matter of
the Project Research (the “Concurrent Research”). In order to clarify the relationship
of the Concurrent Research to the Project Research, ACT specifically
acknowledges and agrees with respect to the Concurrent Research:

 

(a)   the
findings from the Concurrent Research may incorporate data from specimens that
are involved in the Project Research;

 

(b)   the
findings from the Concurrent Research shall not be deemed results of the Project
Research or “Confidential Information” as defined in Section 1.01 of the Agreement;

 

(c)   any
and all products, inventions, and know-how derived from the Concurrent Research
shall not be deemed “Products, Inventions, and Know-how” as defined in Section 1.03
of the Agreement;

 

(d)   the
Principal Research Scientists shall be specifically permitted (without limitation
of any existing rights) to serve as the principal research scientists for, or

 

4

 

participate as a key researcher in, the Concurrent Research
(notwithstanding any contrary implication of Section 2.05 of the
Agreement);

 

(e)   CREW
shall be permitted to receive and use third party materials for the Concurrent
Research (notwithstanding any contrary implication of Section 3.02); and

 

(f)    ACT
has no rights with respect to publication of the findings of the Concurrent Research
or the development of intellectual property from the Concurrent Research

 

4.             MATERIALS

 

4.01         Delivery of Embryos and Other Research Materials. ACT, at
its sole cost and expense, shall provide CREW with reconstructed embryos as
described in the research plan described in Attachment A promptly after the
signing of this Agreement and, thereafter to the extent necessary for CREW to
pursue the Project Research, shall use reasonable and diligent efforts to
supply CREW such reasonable quantities and types of materials (including cell
lines) in ACT’s possession and control as ACT agrees are required to carry out
the Project Research. Any embryos and other research materials delivered to
CREW or its principal research scientist shall remain the property of ACT. Unless
ACT shall otherwise give its prior written consent, CREW and its Project Team shall
not use the embryos or other research materials for any purposes other than to conduct
(a) the Project Research during the Research Term and (b) following
the expiration of the Research Term, such other activities as are expressly
permitted under this Agreement; i.e., the use of the embryos and
research materials to prepare the final research report required by Section 2.03.
Any other uses of the embryos or research materials by CREW and its Project Team
shall be strictly prohibited. In no event, without ACT’s prior written consent,
may CREW provide any such embryos or materials to any other persons or entities.

 

4.02         Third Party Materials. CREW shall not use, or acquire for
use, any third party materials, directly or indirectly, in any Project Research
if the use of such materials would provide such third party with any rights in
any Products, Inventions, and Know-how.

 

5.             TECHNICAL
ASSISTANCE BY ACT

 

5.01         ACT’s
President and Chief Executive Officer (Michael D. West, Ph.D.), its Vice President
of Research (Jose Cibelli, Ph.D.), or other appropriate scientific officer, and
other designated representatives may, from time-to-time, consult with CREW’s
principal research scientist regarding the performance of the Project Research.
In addition, during the course of the Project Research, CREW shall permit
persons designated by ACT to be present as observers while various research
experiments, tests, inspections, and other work hereunder is being conducted.
It is expressly understood that such persons, whether

 

5

 

ACT’s
employees or not, shall not have any supervisory powers over CREW’s principal
research scientist or other members of the Project Team and that, in all
respects, the performance of the Project Research shall be the obligation of
CREW.

 

6.             PAYMENTS

 

6.01         (a)           In
consideration of the undertaking of the Project Research by CREW, unless this Agreement
is sooner terminated as provided herein, ACT shall make the payments to CREW in
the amounts listed in Attachment A in accordance with the payment schedule set
forth in Attachment A.

 

(b)           If the Project Research
has not been completed by June 2, 2000, CREW shall submit to ACT for its
comment and approval a supplemental research plan. ACT shall provide its
comments within ten (10) days from receipt of CREW’s plan and the parties
shall mutually agree on the final, approved plan. Such approved plan shall be
attached and made a part thereof.

 

6.02         Addressee. Payments under this Agreement shall be made by
check payable to:

 

	
  Name on
  check:

  	
   

  
	
  Tax ID#:

  	
   

  
	
  Address:

  	
   

  

 

7.             CONFIDENTIAL
INFORMATION AND PUBLICATIONS

 

7.01         Obligations. During the term of this Agreement and
thereafter, the Receiving Party shall (i) maintain all Confidential
Information in strict confidence, except that the Receiving Party may disclose
or permit the disclosure of any Confidential Information to its directors,
officers, employees, consultants, attorneys and advisors who are obligated to maintain
the confidential nature of such Confidential Information and who need to know such
Confidential Information for the performance of, or as a necessary incident to
the performance of, the Project Research; (ii) implement reasonable
procedures to prohibit the disclosure, unauthorized duplication, misuse or
removal of the other party’s Confidential Information; (iii) use all
Confidential Information solely for the performance of the Project Research;
and (iv) allow its directors, officers, employees, consultants, attorneys
and advisors to reproduce the Confidential Information only to the extent necessary
for the performance of the Project Research, with all such reproductions being considered
Confidential Information. Without limiting the foregoing, each of the parties shall
protect the Confidential Information using at least the same procedures and
degree of care that it uses to prevent the disclosure of its own confidential
information of like importance, but in no event less than reasonable care.
Except as expressly provided in this Agreement, no ownership or license right
is granted in any Confidential Information.

 

7.02         Exceptions. The obligations of the Receiving Party under Section 7.01
above shall not apply to the extent that the Receiving Party can demonstrate
that certain Confidential Information (i) was in the public domain prior
to the time of its disclosure under this Agreement; (ii) entered the
public domain after the time of its disclosure under this

 

6

 

Agreement through means other than an unauthorized disclosure resulting
from an act or omission by the Receiving Party; (iii) was independently
developed or discovered by the Receiving Party without use of the Confidential
Information; (iv) is or was disclosed to the Receiving Party at any time,
whether prior to or after the time of its disclosure under this Agreement, by a
third party having no fiduciary relationship with the Disclosing Party and
having no obligation of confidentiality with respect to such Confidential
Information; or (v) is required to be disclosed to comply with applicable
laws or regulations, or with a court or administrative order, provided that the
Disclosing Party receives reasonable prior written notice of such disclosure.
Additionally, ACT shall have the right to disclose the existence and the terms
of this Agreement without the consent of CREW in any prospectus, offering
memorandum, or other document or filing required by applicable securities laws
or other applicable law or regulation, provided that ACT shall have given CREW
at least ten (10) days prior written notice of the proposed text for the
purpose of giving CREW the opportunity to comment on such text.

 

7.03         Ownership and Return. The Receiving Party acknowledges that
the Disclosing Party (or any third party entrusting its own information to the
Disclosing Party) claims ownership of its Confidential Information in the
possession of the Receiving Party. Upon the expiration or termination of this
Agreement, or at the request of the Disclosing Party at any time, the Receiving
Party shall return to the Disclosing Party all originals, copies, and summaries
of documents, materials, and other tangible manifestations of Confidential Information
in the possession or control of the Receiving Party, except that the Receiving Party
may retain one copy of the Confidential Information in the possession of its
legal counsel solely for the purpose of monitoring its obligations under this
Agreement.

 

7.04         Relief. The Parties acknowledge and agree that any breach of
the confidentiality obligations imposed herein will constitute immediate and
irreparable harm to the party disclosing the Confidential Information and/or
its successors and assigns, which cannot adequately and fully be compensated by
money damages and will warrant, in addition to all other rights and remedies
afforded by law, injunctive relief, specific performance and/or other equitable
relief. The disclosing party’s rights and remedies hereunder are cumulative and
not exclusive. The disclosing party shall also be entitled to receive from the
receiving party the costs of enforcing this paragraph, including reasonable
attorneys’ fees.

 

7.05         Publications. During the term of this Agreement, ACT and
CREW each acknowledge the other party’s interest in publishing certain of its
results to obtain recognition within the scientific community and to advance
the state of scientific knowledge. Each party also recognizes the mutual
interest in obtaining valid patent protection and maintaining as confidential
any nonpatentable materials or methods which would have commercial value when
undisclosed. Consequently, either party, its employees or consultants wishing
to make a publication (including any oral disclosure made without obligation of
confidentiality) relating to work performed by such party as part of the
Project research (the Publishing Party) shall transmit to the other party (the
Reviewing Party) a copy of the proposed written publication at least sixty (60)
days prior to submission for publication, or an outline of such oral disclosure
at least thirty (30) days prior to

 

7

 

presentation.
The Reviewing Party shall have the right (a) to propose modifications to
the publication for patent or other reasons; and (b) to request a delay in
publication in order to protect patentable information. If the Reviewing Party
requests such a delay, the Publishing Party shall delay submission or
presentation of the publication for a period of ninety (90) days to enable
patent applications protecting each party’s rights in such information to be
filed in accordance with Article 8 below. If the Reviewing Party
reasonably claims that such information, whether or not patentable, may have
significant commercial value and can be maintained as a trade secret, the
Publishing Party shall publish or disclose only such information which would
not adversely affect such commercial value. Upon the expiration of sixty (60)
days or thirty (30) days from transmission to the Reviewing Party, the
Publishing Party shall be free to proceed with the written publication or the
presentation, respectively, unless the Reviewing Party has requested the delay
described above. The Parties expressly agree that research grant proposals
submitted to governmental authorities or non-profit organizations shall not be
subject to review under this Section. ACT and CREW agree to recognize each
other in any publications arising out of the Project Research, as appropriate.

 

8.             INTELLECTUAL PROPERTY AND OFFSPRING

 

8.01         (a)  ACT
Technology. All (i) technology, inventions, trade secrets,
know-how, intellectual property, methods, materials, research, techniques or
other confidential or proprietary information relating to ACT’s process for the
genetic manipulation and/or modification of cells and the procedures for
producing cloned embryos, (ii) cell lines, organisms or other materials
which are produced by or incorporate such ACT process, and (iii) modifications,
enhancements or improvements to any of the foregoing by ACT (hereinafter the “ACT
Technology”), shall be the sole and exclusive property of ACT. All U.S. and
foreign intellectual property rights, including all patent rights and rights to
patent applications, relating to the ACT Technology, shall be the sole and
exclusive property of ACT.

 

(b)  CREW Technology.
All (i) technology, inventions, trade secrets, know-how, intellectual
property, methods, materials, research, techniques or other confidential or proprietary
information relating to CREW’s embryo transfer technology, (ii) cell
lines, organisms or other materials which are produced by or incorporate such
CREW technology, and (iii) modifications, enhancements or improvements to
any of the foregoing by CREW (hereinafter the “CREW Technology”), shall be the sole
and exclusive property of CREW. All U.S. and foreign intellectual property
rights, including all patent rights and rights to patent applications, relating
to the CREW Technology, shall be the sole and exclusive property of CREW.

 

(c)  Joint Discoveries.
In the event that CREW and ACT jointly discover any Products, Inventions, and
Know-how during the term of this Agreement (a “Joint Discovery”), and the
parties mutually agree to patent the Joint Discovery, the Parties will jointly
own such Joint Discovery and shall share patent filing, prosecution and
maintenance expenses equally. In the event that one party elects not to jointly
patent the Joint Discovery, the other party shall be free to do so and the
filing party shall pay all expenses associated

 

8

 

with filing, prosecuting, or maintaining the patent application and
patent, and the other party shall fully cooperate, in good faith, with the
filing party.

 

(d)  CREW Discoveries.
Any Products, Inventions, and Know-how independently discovered by CREW during
the term of this Agreement (a “CREW Discovery”) shall be owned by CREW. CREW
shall promptly disclose such CREW Discoveries to ACT. CREW hereby grants to ACT
a first option to obtain an exclusive, worldwide license to any CREW
Discoveries (the “License Option”). ACT may exercise the License Option upon
written notice to CREW within ninety (90) days after the disclosure of the
particular CREW Discovery to ACT. In the event ACT exercises the License
Option, ACT and CREW shall attempt to negotiate in good faith a license
agreement containing commercially reasonable terms consistent with industry
standards. If the parties are unable to reach agreement within ninety (90) days
after the date upon which ACT exercised the License Option (the “Negotiation
Period”), then CREW will be free to offer such rights to third parties;
provided, however, that for a period of one (1) year after the Negotiation
Period, CREW may only offer such rights to third parties on terms which in the
aggregate are no more favorable than those last offered to ACT, unless the more
favorable terms have first been offered in writing to ACT and either (i) ACT
has declined in writing to accept such terms or (ii) ACT has not responded
after a period of thirty (30) days from the date of such offer.

 

8.02         Responsibility for Patents. ACT shall have primary responsibility, at its own expense, for the
preparation, filing, prosecution, and maintenance of all patents and patent applications
derived from the ACT Technology. Title to all such patents and patent applications
shall reside with ACT. CREW shall have primary responsibility, at its own expense,
for the preparation, filing, prosecution, and maintenance of all patents and patent
applications derived from the CREW Technology. Title to all such patents and patent
applications shall reside with CREW. ACT shall have full and complete control over
all ACT Technology matters, and CREW shall have full and complete control over all
CREW. Technology matters. The parties shall cooperate in determining the responsibility
for the preparation, filing, prosecution, and maintenance of all patents and patent
applications derived from Joint Discoveries.

 

8.03         Prompt Disclosure.
CREW shall promptly disclose to ACT, in writing and on a confidential basis,
all Products, Inventions, and Know-how and regularly advise ACT of potentially
patentable or unpatentable technology, inventions, know-how, ideas, and the like.
CREW will cause its Principal Research Scientist and other past and current members
of the Project Team to work closely with ACT to determine which aspects of the
Project Research may be patentable.

 

8.04         Project Team Cooperation. In the event that any Products,
Inventions, and Know-how arise as a result of any of the work done by employees
of CREW and/or its Principal Research Scientist and the members of the Project
Team during the Research Term and for a period of six (6) months
thereafter, CREW shall require and shall require all such persons to agree in
writing to communicate to CREW any facts known to its Principal Research
Scientist or the members of the Project Team related to the Project Research or

 

9

 

to testify in any legal proceedings, sign all applications for patents,
as well as all divisionals, continuations, reissues and foreign applications
thereon, to make all rightful oaths, and generally, to do everything reasonably
required to assist ACT in obtaining and enforcing proper protection for such
rights in all countries.

 

8.05         Other Filings. ACT shall also have the
responsibility for filing all applications which may be required by health or
regulatory authorities relating to the products arising from the Project
Research including, without limitation, filing any application with the U.S. Department
of Agriculture (“USDA”) or the Food and Drug Administration (“FDA”). All costs
and expenses associated with such filings shall be borne solely by ACT. ACT shall
own all right, title, and interest in USDA, FDA or other regulatory approvals
that are obtained by or on behalf of ACT.

 

8.06         Scientist Cooperation. CREW, its employees, its Principal
Research Scientist, and other members of the Research Team shall fully assist
ACT with respect to any filings that may be required by appropriate health or
regulator authorities and shall execute any documentation required with respect
to such filings.

 

8.07         Offspring. All offspring resulting from the Project Research
shall be owned as follows. Litters of offspring produced from cell lines owned
or provided by ACT shall be owned by ACT. Litters of offspring produced from
cell lines owned or provided by CREW shall be owned by CREW. In the event that
the only offspring produced are from cell lines owned or provided by ACT, ACT shall
provide CREW with at least one of such offspring. However, if only one such
offspring is produced, it shall be owned by ACT, but ACT may in its discretion
donate such offspring to the Cincinnati Zoo and Botanical Garden.

 

9.             TERMINATION

 

9.01         Termination at Expiration of Research Term. Unless
previously terminated pursuant to Sections 9.02, 9.03 or extended by the mutual
written consent of the duly authorized representatives of ACT and CREW, this
Agreement shall terminate upon the expiration of the Research Term and
submission of the final written research report required by Section 2.03
hereof.

 

9.02         “With Cause” Termination. ACT may terminate this Agreement
at any time for cause upon ten (10) business days prior written notice to
CREW. “Cause” shall include (a) material breach of this Agreement by CREW where
such breach, if curable, is not remedied to ACT’s reasonable satisfaction
within such ten (10) business day period, or (b) the voluntary or
involuntary termination of CREW’s relationship with, or the physical or mental
incapacity of, both of its Principal Research Scientist.

 

9.04         Termination for Failure to Pay. CREW may terminate this
Agreement only in the event ACT fails to make payments as set forth in Section 6
hereof and fails to cure such nonpayment following receipt of the required
written notice and thirty (30) business day cure period.

 

10

 

9.05         Survivability of Certain Provisions. Notwithstanding any
termination of this Agreement, the obligations of the Parties under Sections
2.03, 2.04, 4, 7, 8, 10 and 11, as well as under any other provisions which by
their nature are intended to survive any such termination, shall survive the
termination of this Agreement and continue to be enforceable. All payments due
under Section 6 up to the date of termination shall be made.

 

10.          REPRESENTATIONS
AND WARRANTIES

 

10.01       No Conflict. Each party warrants and represents to the other
that it has the legal rights and power to enter into this Agreement and to extend
the rights and licenses granted to the other in this Agreement, that the
execution of, and performance of the efforts contemplated by, this Agreement
will not conflict with or result in any breach of any of the terms, conditions,
or provisions of, or constitute a default under, any agreement to which it is a
party or by which it is bound, and that any necessary or appropriate consents or
approvals have been obtained. Each party further represents to the other that
it is not aware of any legal obstacles, including patent rights of others,
which could prevent either party from carrying out the provisions of this
Agreement. During the Research Term, CREW and ACT shall not enter into any
collaboration or other agreement arrangement, take any action, or fail to take
any action that would cause those representations and warranties to be
breached.

 

10.02       Absence of Warranty for Merchantability and Fitness of Project
Research. CREW makes no representations or warranties, express or
implied, concerning the merchantability, or fitness for a particular purpose,
of the Project Research or results.

 

10.03       Absence of Warranty for Merchantability and Fitness of Research
Materials. The materials furnished to CREW by ACT under Section 4
of this Agreement are provided for experimental purposes and may have hazardous
properties. ACT MAKES NO REPRESENTATIONS, AND EXTENDS NO WARRANTIES OF ANY
KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY SUCH MATERIALS. THERE ARE
NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, OR THAT THE USE OF THE MATERIALS WILL NOT INFRINGE ANY PATENT RIGHTS
OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY.

 

10.03       Existence. ACT and CREW each represents to the other that it
is duly incorporated or organized and validly existing as a corporation, or an
Ohio nonprofit corporation in the case of CREW, in good standing under the laws
of its jurisdiction.

 

10.04       Patent Rights. Patent Validity. Nothing in this Agreement
shall be construed as a warranty or representation by either party as to the
validity or scope of any Patent Rights.

 

11

 

10.05       Concurrent Research. CREW represents and warrants that the
Concurrent Research is not directly related to or relevant to the Project Research
or the subject matter of the Project Research.

 

11.          INDEMNIFICATION AND
LIMITATION OF LIABILITY

 

11.1         Indemnification by ACT. ACT agrees, upon receipt of prompt
notice and opportunity to defend, to indemnify and hold CREW harmless, and
hereby forever releases and discharges CREW from and against any and all third
party claims, demands, liabilities, damages, and expenses (including attorney’s
fees) arising out of a breach by ACT of any of its obligations, representations
or warranties hereunder or the negligence of ACT in connection with the work
performed during the Project Research.

 

11.2         Indemnification by CREW. CREW agrees, upon receipt of prompt
notice and opportunity to defend, to indemnify and hold ACT harmless, and
hereby forever releases and discharges ACT from and against any and all third
party claims, demands, liabilities, damages, and expenses (including attorney’s
fees) arising out of a breach by CREW of any of its obligations,
representations or warranties hereunder or the negligence of CREW in connection
with the work performed during the Project Research.

 

11.3         Indemnification Claims. Each party shall give the other
party prompt notice of any claim for which indemnification under this Section 11
is or may be applicable and will cooperate with the indemnifying party in the
defense or settlement of such claim at the indemnifying party’s expense. The
indemnifying party shall be required to provide and be entitled to control the
defense of any claim covered hereunder (including the right to settle it at the
sole discretion of the indemnifying party) with counsel reasonably satisfactory
to the other party which may, at its own expense, participate in the defense of
any claim after the indemnifying party assumes control of the defense thereof.
The indemnification obligations in this Section 11 shall not apply to
amounts paid in settlement of such claim if such settlement is effected without
the consent of the indemnifying party, which consent shall not be unreasonably
withheld or delayed. The failure of the indemnified party to deliver notice to
the indemnifying party promptly after the commencement of any such action, if
prejudicial to the indemnifying party’s ability to defend such action, shall
relieve the indemnifying party of any liability to the indemnified party under
this Section 11, but the failure to promptly deliver notice to the
indemnifying party will not relieve it of any liability that it may have to the
indemnified party other than under this Section 11.

 

11.4         LIMITATION
OF LIABILITY. EXCEPT FOR ANY LIABILITY UNDER SECTIONS 7 (CONFIDENTIALITY)
AND 11 (INDEMNIFICATION), IN NO EVENT SHALL EITHER PARTY (OR ITS SHAREHOLDERS,
DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS) BE LIABLE FOR ANY SPECIAL, INDIRECT,
RELIANCE, INCIDENTAL, EXEMPLARY, PUNITIVE, COVER, OR CONSEQUENTIAL DAMAGES,
INCLUDING LOSS OF PROFITS AND GOODWILL, EVEN IF SUCH PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES, REGARDLESS OF THE THEORY OF LIABILITY.

 

12

 

12.          MISCELLANEOUS

 

12.01       Publicity Restrictions/Press Releases. CREW shall not use
the name of ACT or any of its officers, directors, employees, or agents, or any
adaptation of such names, or any terms of this Agreement in any promotional
material or other public announcement or disclosure without the prior written
consent of ACT. Any press release relating to this Agreement or the Project
Research may be released only upon the prior written approval of the Parties as
to content, accuracy and timing.

 

12.02       Notice to Other Investigators. The Principal Research Scientists shall furnish all investigators
involved in the Project Research, including faculty, staff, students, post-doctoral
fellows and employees, with written notice of their obligations hereunder.

 

12.03       Governing Law. The obligations and rights of the Parties
under this Agreement shall be governed by the laws from time to time enforced
in the Commonwealth of Massachusetts, without regard to principles of conflicts
of law. Any controversy or claim arising out of or relating to this contract,
or the breach thereof, shall be settled by arbitration at a location mutually
agreed upon by the parties in accordance with the Commercial Arbitration Rules of
the American Arbitration Association, and judgment upon the award rendered by
the Arbitrator(s) may be entered in any Court having jurisdiction thereof. Notwithstanding
the foregoing, claims for preliminary injunctive relief or other pre-judgment
remedies may be brought in a state or federal court in the United States with
jurisdiction over the subject matter and parties.

 

12.04       Severability. If any one or more of the provisions of this
Agreement shall be held to be invalid, illegal, or unenforceable, the validity,
legality, or enforceability of the remaining provisions of this Agreement shall
not in any way be affected or impaired thereby.

 

12.05       Waiver. The failure of any Party hereto to insist upon
strict performance of any provision of this Agreement or to exercise any right
hereunder will not constitute a waiver of that provision or right.

 

12.06       Notices. Any notice, communication, or approval required or
permitted to be given or made under this Agreement by one of the Parties to the
other shall be in writing and shall be deemed to have been sufficiently given or
made for all purposes if either (a) mailed by certified mail, postage
prepaid or (b) sent by nationally recognized international delivery service,
if addressed to such other Party at its respective address, as follows:

 

If to CREW:

 

Carl H. Lindner, Jr. Family Center for
Research of Endangered Wildlife

Cincinnati Zoo and Botanical Garden

3400 Vine Street

Cincinnati, Ohio 45220

Attention: Bill Swanson, Ph.D.

 

13

 

If to ACT:

 

Advanced Cell Technology, Inc.

One Innovation Drive

Worcester, Massachusetts 01605

Attention: Jose Cibelli, Ph.D.

 

12.07       Assignment. This Agreement may be assigned by ACT provided
that any assignee shall assume all rights and duties of ACT hereunder. This
Agreement may not be assigned or delegated by CREW.

 

12.08       Import/Export. CREW shall comply fully with any and all
applicable local, state, federal and international laws and regulations
relating to the Products, Inventions, and Know-how, including without
limitation all export or import regulations and rules now in effect or as
may be issued from time to time by any governmental authority which has
jurisdiction relating to the export of technology relating to the Products,
Inventions, and Know-how.

 

12.09       Independent Contractors. ACT and CREW each shall, at all
times, act as independent parties and nothing contained in this Agreement shall
be construed or implied to create an agency or partnership. No Party shall have
the authority to contract or incur expenses on behalf of the other, except as
may be expressly authorize by ancillary agreements. CREW’s principal research
scientist and members of the Project Team shall not be deemed to be employees
of ACT.

 

12.10       Force Majeure. Neither party shall be in default of its
obligations hereunder to the extent that its performance is delayed or
prevented by causes beyond its control, including but not limited to, acts of
God and interruptions in telecommunication services.

 

12.11       Headings. Headings used in this Agreement are for
convenience only and shall not be considered in construing or interpreting this
Agreement.

 

12.12       Entire Agreement. The terms and conditions herein constitute
the entire agreement between the Parties and shall supersede all previous
agreements, proposed term sheets, and discussions, either oral or written,
between the Parties with respect to the subject matter of this Agreement. No
amendment, alteration, or modification of this Agreement or any attachments to
this Agreement shall be valid unless executed in writing by authorized
signatories of the Parties.

 

[The Remainder of this Page Has Been
Intentionally Left Blank]

 

 

14

 

IN WITNESS WHEREOF, ACT and
CREW have caused this Agreement to be executed in duplicate counterpart
originals by their duly authorized officers to be effective as of the date
first written above.

 

	
  THE CARL H. LINDNER, JR.

  	
  ADVANCED CELL TECHNOLOGY,
  INC.

  
	
  FAMILY CENTER FOR RESEARCH

  
	
  OF ENDANGERED WILDLIFE,

  
	
  THE RESEARCH DIVISION OF

  
	
  THE CINCINNATI ZOO AND

  
	
  BOTANICAL GARDEN

  

 

 

	
  By:

  	
  /s/ Terri L. Roth

  	
   

  	
  By:

  	
  /s/ Jose Cibelli

  	
   

  
	
  Name:

  	
  Terri L. Roth, Ph.D.

  	
  Name:

  	
  Jose Cibelli

  
	
  Title:

  	
  Director of Research

  	
  Title:

  	
  VP Research

  
									

 

 

I
hereby acknowledge and agree to the terms of Sections 2, 6 and 7 and
Subsections 11.02 of this Agreement, and I reaffirm that I will assign to CREW
all of my right, title, and interest in any CREW Discoveries.

 

	
  ACKNOWLEDGED AND AGREED:

  
	
   

  
	
   

  
	
  /s/ Bill Swanson

  	
   

  
	
  Dr. Bill Swanson

  
	
  Principal Research
  Scientist

  
	
   

  
	
   

  
	
  /s/ Terri Roth

  	
   

  
	
  Dr. Terri Roth

  
	
  Principal Research
  Scientist

  

 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]